AllBioSyn

Since its establishment in 2023, AllBioSyn has been committed to the vision of "protecting human health with innovative pharmaceutical technologies," focusing on technical breakthroughs and product innovation in the field of small nucleic acid drugs. The company's core team consists of senior scientists with over 20 years of experience in pharmaceutical R&D, medical experts with extensive clinical experience, and industry veterans with management experience in multinational pharmaceutical companies. They have accumulated deep technical reserves and project experience in key technologies such as: new multi-phosphorylation technology, green nucleic acid synthesis technology (enzyme catalysis technology, crystallization, and purification processes), RNA cyclization modification technology, nucleic acid drug molecular building block technology, selective nucleic acid drug delivery technology, enzyme-catalyzed Oligo synthesis technology, and small nucleic acid liquid-phase synthesis technology.